Lidocaine and Prilocaine Aerosol Approved for Clinical Trials
June 2, 2025
Source: drugdu
57
On May 29, Fuyuan Pharmaceutical(601089) issued an announcement that its wholly-owned subsidiary Fuyuan Pharmaceutical Co., Ltd. received the "Drug Clinical Trial Approval Notice" for Lidocaine Prilocaine Aerosol approved and issued by the State Drug Administration. Lidocaine Prilocaine Aerosol meets the relevant requirements for drug registration and is approved for clinical trials.
Fuyuan Pharmaceutical Co., Ltd. has applied for clinical trials for lidocaine prilocaine aerosol, which is suitable for the treatment of primary premature ejaculation in adult men. The route of administration is local, and the registration classification is chemical drug class 3. So far, Fuyuan Pharmaceutical has invested approximately RMB 9.5477 million in the research and development of this product.
In the first quarter of 2025, Fuyuan Pharmaceutical achieved revenue of 830 million yuan and net profit attributable to shareholders of the parent company of 131 million yuan.
https://finance.eastmoney.com/a/202505293418053486.html
Copyright©2025 Ddu. All rights reserved.
Read more on
- The application for the marketing approval of the innovative drug in the field of autoimmune diseases jointly developed with Connect Biopharmaceuticals has been accepted July 10, 2025
- Kanghua Biopharma terminates cooperation in tuberculosis and rabies vaccine research and development July 10, 2025
- Small nucleic acid therapy challenges GLP-1 giants July 10, 2025
- Baili Tianheng BL-B01D1 Update Progress July 10, 2025
- FDA Approves KalVista Pharmaceuticals’ Ekterly for Hereditary Angioedema July 10, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
